# Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

*PRI Rank #17 · Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026/rank-17*

| Field | Value |
| --- | --- |
| Rank | #17 |
| 18m citations | 28 |
| Journal | Nature Communications |
| Year | 2024 |
| DOI | 10.1038/s41467-024-53837-7 |
| Corresponding authors | Ciara Metcalfe, Nicholas C. Turner |
| Institution | The Institute of Cancer Research, United Kingdom |

**Ranking page:** [Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026](https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026)

**Paper link:** [10.1038/s41467-024-53837-7](https://doi.org/10.1038/s41467-024-53837-7)

## Topics

GPX4 · CDK4/6 inhibitor · endocrine therapy · estrogen receptor positive breast cancer · palbociclib · giredestrant · Ferroptosis · genome-wide CRISPR screens · oxidative stress · lipid peroxidation · AGPAT3 · ACSL4 · triple negative breast cancer · CDK4/6 inhibitor resistance · lipid metabolism · peroxisome · Cytostasis · GPX4 inhibition

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Estrogen and related hormone effects Papers, Class of 2026. https://pri.pepkio.com/top-papers/estrogen-and-related-hormone-effects/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```